comparemela.com

Page 5 - Avion Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ImmuPharma submits phase 2/3 protocol to US FDA for Lupuzor treatment

ImmuPharma PLC on Monday said it submitted a phase 2/3 clinical trial protocol to the US Food & Drug Administration testing the Lupuzor treatment for lupus patients. The London-based drug. | March 27, 2023

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

ImmuPharma expects new Lupozor study to begin in H2 2023

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive s London studio after announcing that its partner Avion.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.